SERA
Sera Prognostics Inc
NASDAQ: SERA · HEALTHCARE · MEDICAL DEVICES
$2.07
+0.98% today
Updated 2026-10-07
Market cap
$78.90M
P/E ratio
—
P/S ratio
1,127.13x
EPS (TTM)
$-0.67
Dividend yield
—
52W range
$2 – $4
Volume
0.0M
WallStSmart proprietary scores
35
out of 100
Grade: D
Sell
Investment rating
5.3
Growth
C+5.5
Quality
C+2.5
Profitability
F4.0
Valuation
C2/9
Piotroski F-Score
Weak
-3.4
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →274 stocks currently score above 75
Price targets
Analyst target
$5.50
+165.70%
12-Month target
—
—
Intrinsic (DCF)
$1.49
Margin of safety
-73.83%
0 Strong Buy4 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Revenue growth 76.50% QoQ
+ Debt/equity 0.05x — low leverage
Risks
- Piotroski 2/9 — weak financial health
- Altman Z -3.41 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-6.33M
- 73.83% above intrinsic value
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $268000.00 | $306000.00 | $77000.00 | $81000.00 | $70000.00 |
| Net income | $-44.19M | $-36.24M | $-32.90M | $-31.93M | $-9.14M |
| EPS | — | — | — | — | $-0.67 |
| Free cash flow | $-35.40M | $-27.32M | $-15.29M | $-26.35M | $-6.33M |
| Profit margin | -16,487.31% | -11,843.79% | -42,724.68% | -39,417.28% | — |
Peer comparison
Smart narrative
Sera Prognostics Inc trades at $2.07. Our Smart Value Score of 35/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -3.41, it sits in the distress. TTM revenue stands at $70000.00. Our DCF model estimates intrinsic value at $1.49.
Frequently asked questions
What is Sera Prognostics Inc's stock price?
Sera Prognostics Inc (SERA) trades at $2.07, on a P/S of 1,127.1x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Sera Prognostics Inc overvalued?
Sera Prognostics Inc carries a Smart Value Score of 35/100 (Grade D), which we rate Sell. That score blends growth, quality, and valuation into one read. On valuation specifically, our conservative DCF puts intrinsic value at $1.49 against the $2.07 price, so on cash flow terms the market is paying a premium for Sera Prognostics Inc's growth. The Sell rating reflects that growth and quality, while the DCF flags that the price already assumes a lot.
What is the price target of Sera Prognostics Inc (SERA)?
The 12-month analyst consensus target is $5.50, about 165.7% above the current $2.07. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the intrinsic value of Sera Prognostics Inc (SERA)?
Our DCF model estimates intrinsic value at $1.49, a -73.8% margin of safety versus today's $2.07. Intrinsic value is what the projected cash flows are worth today. A negative reading means the price is running ahead of that conservative estimate, leaving little downside cushion if growth slows.
What is Sera Prognostics Inc's revenue?
Sera Prognostics Inc's trailing twelve-month revenue is $70000.00. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Sera Prognostics Inc's Altman Z-Score is -3.41, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryMEDICAL DEVICES
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio1,127.13x
ROE-47.53%
Beta1.06
50D MA$2.05
200D MA$2.27
Shares out0.04B
Float0.03B
Short ratio—
Avg volume0.0M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—